search
Back to results

Lumbar Spine Muscle Degeneration Inhibits Rehabilitation-Induced Muscle Recovery

Primary Purpose

Disc Degeneration, Low Back Pain

Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Exercise
Sponsored by
University of California, San Diego
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Disc Degeneration focused on measuring Multifidus, Muscle, Degeneration, Lumbar Spine, Disc

Eligibility Criteria

21 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Spine pathologies requiring un-instrumented surgery (i.e. laminectomy, laminoforaminotomy, or discectomy).
  • Age 21-85 years of age.

Exclusion Criteria:

  • History of lumbar spine surgery.
  • Patients requiring placement of instrumentation as part of the surgical procedure (i.e. fusion).
  • Diabetes.
  • Neuromuscular diseases.

Sites / Locations

  • UC San Diego

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Exercise

Non-exercise

Arm Description

A single bout of moderate intensity lumbar extensor muscle exercise.

No exercise intervention.

Outcomes

Primary Outcome Measures

Change in Multifidus Muscle Fatty Infiltration
(% fat at 6 months - % fat at baseline / % fat at baseline)

Secondary Outcome Measures

Change in Oswestry Disability Index (ODI)
Disability Questionnaire (10 questions, % scale is sum of 10 questions/50, higher score is worse), 6 months - baseline
Change in Fear Avoidance Beliefs Questionnaire (FABQ)
Fear Avoidance Behaviors (sumo 16 items, 0-64 scale, higher score is worse), 6 months- baseline
Change in Pain Catastrophizing Scale (PCS)
Pain behaviors questionnaire (sum of 13 items, 0-52 scale, higher score is worse), 6 months - baseline
Change in Activated Muscle Volume (%)
(% muscle activation after exercise - % muscle activation at baseline / % muscle activation at baseline)
Change in Pain (VAS)
Visual Analog Scale (0-100 mm scale), 6 months - baseline
Change in Strength
MedEx dynamometer, Back Extensor Strength (Nm), 6 months - baseline
MYHC3 gene expression (delta CT/delta CT)
Embryonic myosin heavy chain gene expression
MHY3 protein abundance (ug/mg)
Embryonic myosin heavy chain protein abundance
MYOG gene expression (delta CT/delta CT)
Myogenin gene expression
MYOG protein abundance (ug/mg)
Myogenin protein abundance
PAX7 gene expression (delta CT/delta CT)
PAX7 gene expression
PAX7 gene expression (ug/mg)
PAX7 protein abundance
ANKRD2 gene expression (delta CT/delta CT)
ANKRD2 gene expression
ANKRD2 protein abundance (ug/mg)
ANKRD2 protein abundance
MTOR gene expression (delta CT/delta CT)
MTOR gene expression
MTOR protein abundance (ug/mg)
MTOR protein abundance
COL1A1 gene expression (delta CT/delta CT)
COL1A1 gene expression
COL3A1 gene expression (delta CT/delta CT)
COL3A1 gene expression
COL9A1 gene expression (delta CT/delta CT)
COL9A1 gene expression
LOX gene expression (delta CT/delta CT)
LOX gene expression
CTGF gene expression (delta CT/delta CT)
CTGF gene expression
TGFB1 gene expression (delta CT/delta CT)
TGFB1 gene expression
MMP1 gene expression (delta CT/delta CT)
MMP1 gene expression
MMP3 gene expression (delta CT/delta CT)
MMP3 gene expression
MMP9 gene expression (delta CT/delta CT)
MMP9 gene expression
CEBPA gene expression (delta CT/delta CT)
CEBPA gene expression
FABP4 gene expression (delta CT/delta CT)
FABP4 gene expression
PPARG gene expression (delta CT/delta CT)
PPARG gene expression
PPARD gene expression (delta CT/delta CT)
PPARD gene expression
LEP gene expression (delta CT/delta CT)
LEP gene expression
ADIPOQ gene expression (delta CT/delta CT)
ADIPOQ gene expression
CASP1 gene expression (delta CT/delta CT)
CASP1 gene expression
CASP3 gene expression (delta CT/delta CT)
CASP3 gene expression
TNFa gene expression (delta CT/delta CT)
TNFa gene expression
IL10 gene expression (delta CT/delta CT)
IL10 gene expression
IL6 gene expression (delta CT/delta CT)
IL6 gene expression
IL1B gene expression (delta CT/delta CT)
IL1B gene expression
COL1A1 Protein abundance (ug/mg)
COL1A1 Protein abundance
COL3A1 Protein abundance (ug/mg)
COL3A1 Protein abundance
COL9A1 Protein abundance (ug/mg)
COL9A1 Protein abundance
LOX Protein abundance (ug/mg)
LOX Protein abundance
CTGF Protein abundance (ug/mg)
CTGF Protein abundance
TGFB1 Protein abundance (ug/mg)
TGFB1 Protein abundance
MMP1 Protein abundance (ug/mg)
MMP1 Protein abundance
MMP3 Protein abundance (ug/mg)
MMP3 Protein abundance
MMP9 Protein abundance (ug/mg)
MMP9 Protein abundance
CEBPA Protein abundance (ug/mg)
CEBPA Protein abundance
FABP4 Protein abundance (ug/mg)
FABP4 Protein abundance
PPARG Protein abundance (ug/mg)
PPARG Protein abundance
PPARD Protein abundance (ug/mg)
PPARD Protein abundance
LEP Protein abundance (ug/mg)
LEP Protein abundance
ADIPOQ Protein abundance (ug/mg)
ADIPOQ Protein abundance
CASP1 Protein abundance (ug/mg)
CASP1 Protein abundance
CASP3 Protein abundance (ug/mg)
CASP3 Protein abundance
TNFa Protein abundance (ug/mg)
TNFa Protein abundance
IL10 Protein abundance (ug/mg)
IL10 Protein abundance
IL6 Protein abundance (ug/mg)
IL6 Protein abundance
IL1B Protein abundance (ug/mg)
IL1B Protein abundance
Change in Multifidus muscle volume (%)
Multifidus muscle volume (cc), (6 months - baseline/baseline)

Full Information

First Posted
February 9, 2018
Last Updated
July 27, 2023
Sponsor
University of California, San Diego
Collaborators
Balgrist University Hospital, Spine Institute of San Diego (Spine Zone)
search

1. Study Identification

Unique Protocol Identification Number
NCT03442374
Brief Title
Lumbar Spine Muscle Degeneration Inhibits Rehabilitation-Induced Muscle Recovery
Official Title
Lumbar Spine Muscle Degeneration Inhibits Rehabilitation-Induced Muscle
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
July 1, 2019 (Actual)
Primary Completion Date
June 1, 2023 (Actual)
Study Completion Date
August 1, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of California, San Diego
Collaborators
Balgrist University Hospital, Spine Institute of San Diego (Spine Zone)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Low back pain (LBP) is a complex condition that affects 65-85% of the population, and is the leading musculoskeletal condition contributing to disability in the United States. Disc herniation is the most common injury and 75% of individuals undergoing surgical and rehabilitative interventions for this condition experience suboptimal or poor outcomes. These patients demonstrate disability and deficits in functional capacity, including strength and endurance of the lumbar musculature. Muscle-specific changes in individuals with LBP include altered muscle volume, fatty infiltration and fibrosis, and fiber area and type. Importantly, these changes are insensitive to rehabilitation in patients with continued chronic or recurrent symptoms. While normal disuse-related atrophy in the presence of LBP is expected, more severe or chronic pathology, such as inflammation and fiber damage, may be inducing irreversible fiber degeneration and fatty/fibrotic tissue changes that impair muscle function and recovery. While the structural and adaptive capacities of healthy muscle are well understood, muscle recovery in the presence of pathology is less clear. To address this gap in knowledge, the purpose of this project is to compare structural, physiological, and adaptive responses of muscle in the presence of acute and chronic lumbar spine pathology. The central hypothesis is that chronic injury results in a state of muscle inflammation, atrophy, fibrosis, and muscle degeneration that is not responsive to exercise. The Investigators will identify which patients respond to exercise by examining muscle hypertrophic, fibrotic, inflammatory, and adipogenic gene expression profiles. Patients will be followed for six months post-operatively to measure muscle recovery and strength.
Detailed Description
AIM: To determine the effect of exercise on induction of muscle hypertrophic, fibrotic, inflammatory, and adipogenic pathways in patients with mild versus severe fatty infiltration of the multifidus muscle. Rationale. The objectives of this aim are to 1) measure molecular responses of muscle to a well-defined bout of pre-operative exercise, and 2) to determine if baseline morphological or exercise-induced molecular responses predict muscle structural recovery and functional gains up to 6 months post-operatively. Design. This will be a longitudinal study of 40 patients with mild (< 20%) versus severe (> 50%) fatty infiltration. Non-exercise controls will also be important and the investigators intend to use a portion of biopsied tissue from other experiments as additional controls. Prior to surgery, patients will undergo clinical and MRI examinations. Additionally, patients will undergo an exercise bout 6 hours pre-operatively, and then immediately undergo a short MRI imaging protocol to measure exercise-induced perfusion changes (IVIM). Six hours after the exercise bout, the investigators will collect biopsies of the multifidus during surgery to characterize the hypertrophic, fibrotic, adipogenic, and inflammatory responses. For primary analyses, patient groups will be selected on the basis of severity of muscle fatty infiltration. Group ages and genders will be matched because the investigators know that baseline and exercise-induced gene expression varies with age. Surgical procedure and manipulation of the disc intraoperatively will be documented to account for the potential for disc and other surgery-specific effects on muscle structure. Six months post-operatively, repeated measures of muscle structure will be made via MRI. At 6, 12, and 24 weeks, strength (isokinetic dynamometer) and patient-specific function (questionnaire data) will be obtained as per standard protocol. Methods: Physical Examination: A physical therapist with spine injury experience will conduct the clinical exam. Age, gender and body mass index (BMI), duration of symptoms, anti-inflammatory drug use, active and passive range of motion, provocative neural tension tests (measuring joint range of motion [ROM]), strength and endurance as measured on an isokinetic dynamometer (MedX Holdings Inc.), neurovascular status, Oswestry Disability Index (81), Baecke Physical Activity Questionnaire (BPA), Fear Avoidance Beliefs Questionnaire (FABQ), and Pain Catastrophizing Scale (PCS) are important measures that capture both physical and psychosocial factors known to be related to LBP and will be collected at the clinical site. This screen will be used to confirm that discogenic symptoms are isolated to levels below L4, which allows us to use vastus lateralis as an internal control muscle biopsy. Clinical MRI: Standard axial, sagittal oblique, and coronal oblique MR images of the spine will be collected on all patients who are scheduled for surgery. To identify disc injury severity (Pfirrmann grade), muscle fatty infiltration (Kjaer grade), and to confirm injury location, T1 and T2 non-fat suppressed or contrast-enhanced axial and sagittal MR images of the spine joint will be used. Multimodal MRI: Imaging will be performed in a single session on a state-of-the-art 3T MRI system (GE MR750). The quantity and distribution of spine muscle volume, fat volume, and connective tissue volume will be performed from supine scans using high-resolution (1mm3) 3D FSPGR, IDEAL fat-water separation, and UTE pulse sequences, respectively using a 32-channel spine array coil. IVIM will be used to quantify regional muscle activation in response to an exercise bout. Exercise protocol: Prior to surgery, patients will be subjected to a lumbar spine exercise protocol on a MedX Lumbar extension dynamometer with a pelvic restraint system allowing for isolation of lumbar spine muscles. The exercise protocol consists of 1 set of 20 repetitions (range 15-25 reps) at a rate of 5 seconds/repetitions with a starting weight of 60-80% of their computerized strength score. Patients will be instructed to target an exertion level of 7/10 on the Borg Rate of Perceived Exertion (RPE) scale within their available passive ROM range into flexion-extension. Diet protocol: Importantly, the patients will remain NPO (no food or water) after the exercise bout but will have a standardized diet for 24 hours prior to the exercise bout and surgery, which mitigates the effects of diet on gene expression (137, 150-152). Evening meals will be standardized (1900h: 11 kcal/kg; 60% carbohydrate [CHO], 25% fat [FAT], 15% protein [PRO]; 2200h (3 kcal/kg; 95% CHO, 2% FAT, 3% PRO) because meal composition can acutely impact gene and protein expression. Harvesting and storage of muscle biopsy: Muscle biopsies will be harvested within 6 hours of the exercise bout at their scheduled surgery time. Subjects will be excluded from the analysis if their biopsies are not harvested within 1 hour of the prescribed time point. Biopsies will be obtained with a standard biopsy clamp at the middle and deep margins of the multifidus muscle as noted in Aim #1 and immediately placed in RNAlater (Qiagen) for subsequent qPCR analysis or frozen in liquid nitrogen for protein abundance/phosphorylation measurements. qPCR and western blotting: Gene expression and protein abundance will be measured by, qPCR and western blotting, respectively. Briefly, real-time PCR will be performed in a Bio-Rad CFX384 using customized plates (PrimePCR, Bio-Rad). Target gene expression will be calculated relative to values from 18S ribosomal subunit, as preliminary findings demonstrate it to be more stable than glyceraldehyde-3-phosphate dehydrogenase (GAPDH; data not presented). For genes in which we find a greater than 3-fold change in expression, western blotting will be used to assess protein abundance, as previously described.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Disc Degeneration, Low Back Pain
Keywords
Multifidus, Muscle, Degeneration, Lumbar Spine, Disc

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Stratified by fatty infiltration severity (n=20/group x 2 groups + non exercise controls n=20)
Masking
Outcomes Assessor
Allocation
Non-Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Exercise
Arm Type
Experimental
Arm Description
A single bout of moderate intensity lumbar extensor muscle exercise.
Arm Title
Non-exercise
Arm Type
No Intervention
Arm Description
No exercise intervention.
Intervention Type
Other
Intervention Name(s)
Exercise
Intervention Description
The exercise protocol consists of 1 set of 20 repetitions (range 15-25 reps) at a rate of 5 seconds/repetitions with a starting weight of 60-80% of their computerized strength score. Patients will be instructed to target an exertion level of 7/10 on the Borg Rate of Perceived Exertion (RPE) scale within their available passive ROM range into flexion-extension
Primary Outcome Measure Information:
Title
Change in Multifidus Muscle Fatty Infiltration
Description
(% fat at 6 months - % fat at baseline / % fat at baseline)
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Change in Oswestry Disability Index (ODI)
Description
Disability Questionnaire (10 questions, % scale is sum of 10 questions/50, higher score is worse), 6 months - baseline
Time Frame
6 Months
Title
Change in Fear Avoidance Beliefs Questionnaire (FABQ)
Description
Fear Avoidance Behaviors (sumo 16 items, 0-64 scale, higher score is worse), 6 months- baseline
Time Frame
6 months
Title
Change in Pain Catastrophizing Scale (PCS)
Description
Pain behaviors questionnaire (sum of 13 items, 0-52 scale, higher score is worse), 6 months - baseline
Time Frame
6 months
Title
Change in Activated Muscle Volume (%)
Description
(% muscle activation after exercise - % muscle activation at baseline / % muscle activation at baseline)
Time Frame
After exercise (within 5 minutes)
Title
Change in Pain (VAS)
Description
Visual Analog Scale (0-100 mm scale), 6 months - baseline
Time Frame
6 months
Title
Change in Strength
Description
MedEx dynamometer, Back Extensor Strength (Nm), 6 months - baseline
Time Frame
6 months
Title
MYHC3 gene expression (delta CT/delta CT)
Description
Embryonic myosin heavy chain gene expression
Time Frame
6 hours after a single exercise bout
Title
MHY3 protein abundance (ug/mg)
Description
Embryonic myosin heavy chain protein abundance
Time Frame
6 hours after a single exercise bout
Title
MYOG gene expression (delta CT/delta CT)
Description
Myogenin gene expression
Time Frame
6 hours after a single exercise bout
Title
MYOG protein abundance (ug/mg)
Description
Myogenin protein abundance
Time Frame
6 hours after a single exercise bout
Title
PAX7 gene expression (delta CT/delta CT)
Description
PAX7 gene expression
Time Frame
6 hours after a single exercise bout
Title
PAX7 gene expression (ug/mg)
Description
PAX7 protein abundance
Time Frame
6 hours after a single exercise bout
Title
ANKRD2 gene expression (delta CT/delta CT)
Description
ANKRD2 gene expression
Time Frame
6 hours after a single exercise bout
Title
ANKRD2 protein abundance (ug/mg)
Description
ANKRD2 protein abundance
Time Frame
6 hours after a single exercise bout
Title
MTOR gene expression (delta CT/delta CT)
Description
MTOR gene expression
Time Frame
6 hours after a single exercise bout
Title
MTOR protein abundance (ug/mg)
Description
MTOR protein abundance
Time Frame
6 hours after a single exercise bout
Title
COL1A1 gene expression (delta CT/delta CT)
Description
COL1A1 gene expression
Time Frame
6 hours after a single exercise bout
Title
COL3A1 gene expression (delta CT/delta CT)
Description
COL3A1 gene expression
Time Frame
6 hours after a single exercise bout
Title
COL9A1 gene expression (delta CT/delta CT)
Description
COL9A1 gene expression
Time Frame
6 hours after a single exercise bout
Title
LOX gene expression (delta CT/delta CT)
Description
LOX gene expression
Time Frame
6 hours after a single exercise bout
Title
CTGF gene expression (delta CT/delta CT)
Description
CTGF gene expression
Time Frame
6 hours after a single exercise bout
Title
TGFB1 gene expression (delta CT/delta CT)
Description
TGFB1 gene expression
Time Frame
6 hours after a single exercise bout
Title
MMP1 gene expression (delta CT/delta CT)
Description
MMP1 gene expression
Time Frame
6 hours after a single exercise bout
Title
MMP3 gene expression (delta CT/delta CT)
Description
MMP3 gene expression
Time Frame
6 hours after a single exercise bout
Title
MMP9 gene expression (delta CT/delta CT)
Description
MMP9 gene expression
Time Frame
6 hours after a single exercise bout
Title
CEBPA gene expression (delta CT/delta CT)
Description
CEBPA gene expression
Time Frame
6 hours after a single exercise bout
Title
FABP4 gene expression (delta CT/delta CT)
Description
FABP4 gene expression
Time Frame
6 hours after a single exercise bout
Title
PPARG gene expression (delta CT/delta CT)
Description
PPARG gene expression
Time Frame
6 hours after a single exercise bout
Title
PPARD gene expression (delta CT/delta CT)
Description
PPARD gene expression
Time Frame
6 hours after a single exercise bout
Title
LEP gene expression (delta CT/delta CT)
Description
LEP gene expression
Time Frame
6 hours after a single exercise bout
Title
ADIPOQ gene expression (delta CT/delta CT)
Description
ADIPOQ gene expression
Time Frame
6 hours after a single exercise bout
Title
CASP1 gene expression (delta CT/delta CT)
Description
CASP1 gene expression
Time Frame
6 hours after a single exercise bout
Title
CASP3 gene expression (delta CT/delta CT)
Description
CASP3 gene expression
Time Frame
6 hours after a single exercise bout
Title
TNFa gene expression (delta CT/delta CT)
Description
TNFa gene expression
Time Frame
6 hours after a single exercise bout
Title
IL10 gene expression (delta CT/delta CT)
Description
IL10 gene expression
Time Frame
6 hours after a single exercise bout
Title
IL6 gene expression (delta CT/delta CT)
Description
IL6 gene expression
Time Frame
6 hours after a single exercise bout
Title
IL1B gene expression (delta CT/delta CT)
Description
IL1B gene expression
Time Frame
6 hours after a single exercise bout
Title
COL1A1 Protein abundance (ug/mg)
Description
COL1A1 Protein abundance
Time Frame
6 hours after a single exercise bout
Title
COL3A1 Protein abundance (ug/mg)
Description
COL3A1 Protein abundance
Time Frame
6 hours after a single exercise bout
Title
COL9A1 Protein abundance (ug/mg)
Description
COL9A1 Protein abundance
Time Frame
6 hours after a single exercise bout
Title
LOX Protein abundance (ug/mg)
Description
LOX Protein abundance
Time Frame
6 hours after a single exercise bout
Title
CTGF Protein abundance (ug/mg)
Description
CTGF Protein abundance
Time Frame
6 hours after a single exercise bout
Title
TGFB1 Protein abundance (ug/mg)
Description
TGFB1 Protein abundance
Time Frame
6 hours after a single exercise bout
Title
MMP1 Protein abundance (ug/mg)
Description
MMP1 Protein abundance
Time Frame
6 hours after a single exercise bout
Title
MMP3 Protein abundance (ug/mg)
Description
MMP3 Protein abundance
Time Frame
6 hours after a single exercise bout
Title
MMP9 Protein abundance (ug/mg)
Description
MMP9 Protein abundance
Time Frame
6 hours after a single exercise bout
Title
CEBPA Protein abundance (ug/mg)
Description
CEBPA Protein abundance
Time Frame
6 hours after a single exercise bout
Title
FABP4 Protein abundance (ug/mg)
Description
FABP4 Protein abundance
Time Frame
6 hours after a single exercise bout
Title
PPARG Protein abundance (ug/mg)
Description
PPARG Protein abundance
Time Frame
6 hours after a single exercise bout
Title
PPARD Protein abundance (ug/mg)
Description
PPARD Protein abundance
Time Frame
6 hours after a single exercise bout
Title
LEP Protein abundance (ug/mg)
Description
LEP Protein abundance
Time Frame
6 hours after a single exercise bout
Title
ADIPOQ Protein abundance (ug/mg)
Description
ADIPOQ Protein abundance
Time Frame
6 hours after a single exercise bout
Title
CASP1 Protein abundance (ug/mg)
Description
CASP1 Protein abundance
Time Frame
6 hours after a single exercise bout
Title
CASP3 Protein abundance (ug/mg)
Description
CASP3 Protein abundance
Time Frame
6 hours after a single exercise bout
Title
TNFa Protein abundance (ug/mg)
Description
TNFa Protein abundance
Time Frame
6 hours after a single exercise bout
Title
IL10 Protein abundance (ug/mg)
Description
IL10 Protein abundance
Time Frame
6 hours after a single exercise bout
Title
IL6 Protein abundance (ug/mg)
Description
IL6 Protein abundance
Time Frame
6 hours after a single exercise bout
Title
IL1B Protein abundance (ug/mg)
Description
IL1B Protein abundance
Time Frame
6 hours after a single exercise bout
Title
Change in Multifidus muscle volume (%)
Description
Multifidus muscle volume (cc), (6 months - baseline/baseline)
Time Frame
baseline

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Spine pathologies requiring un-instrumented surgery (i.e. laminectomy, laminoforaminotomy, or discectomy). Age 21-85 years of age. Exclusion Criteria: History of lumbar spine surgery. Patients requiring placement of instrumentation as part of the surgical procedure (i.e. fusion). Diabetes. Neuromuscular diseases.
Facility Information:
Facility Name
UC San Diego
City
La Jolla
State/Province
California
ZIP/Postal Code
92093
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Lumbar Spine Muscle Degeneration Inhibits Rehabilitation-Induced Muscle Recovery

We'll reach out to this number within 24 hrs